- Home
- CMPR vs NVCR Comparison
CMPR vs NVCR Comparison
Compare CMPR & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPR
- NVCR
- Stock Information
- Founded
- CMPR 1994
- NVCR 2000
- Country
- CMPR Ireland
- NVCR Switzerland
- Employees
- CMPR N/A
- NVCR N/A
- Industry
- CMPR Publishing
- NVCR Medical/Dental Instruments
- Sector
- CMPR Consumer Discretionary
- NVCR Health Care
- Exchange
- CMPR Nasdaq
- NVCR Nasdaq
- Market Cap
- CMPR 1.1B
- NVCR 1.9B
- IPO Year
- CMPR N/A
- NVCR 2015
- Fundamental
- Price
- CMPR $48.07
- NVCR $17.60
- Analyst Decision
- CMPR Strong Buy
- NVCR Buy
- Analyst Count
- CMPR 2
- NVCR 7
- Target Price
- CMPR $62.50
- NVCR $32.43
- AVG Volume (30 Days)
- CMPR 328.5K
- NVCR 1.3M
- Earning Date
- CMPR 07-30-2025
- NVCR 07-24-2025
- Dividend Yield
- CMPR N/A
- NVCR N/A
- EPS Growth
- CMPR 83.61
- NVCR N/A
- EPS
- CMPR 5.97
- NVCR N/A
- Revenue
- CMPR $3,366,207,000.00
- NVCR $621,711,000.00
- Revenue This Year
- CMPR $4.65
- NVCR $5.56
- Revenue Next Year
- CMPR $3.16
- NVCR $9.19
- P/E Ratio
- CMPR $8.00
- NVCR N/A
- Revenue Growth
- CMPR 3.64
- NVCR 18.27
- 52 Week Low
- CMPR $35.21
- NVCR $14.17
- 52 Week High
- CMPR $104.92
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- CMPR 56.48
- NVCR 49.74
- Support Level
- CMPR $45.73
- NVCR $16.81
- Resistance Level
- CMPR $50.48
- NVCR $18.59
- Average True Range (ATR)
- CMPR 1.97
- NVCR 0.74
- MACD
- CMPR 0.14
- NVCR 0.08
- Stochastic Oscillator
- CMPR 69.47
- NVCR 56.18
About CMPR Cimpress plc (Ireland)
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.